Clinical trials: Resistant Major Depression
Treatment Resistant Depression
Epidural Cortical Stimulation for Depression
Objective: Chronic epidural cortical stimulation (ECS) involves the neurosurgical placement of an electric wire on the surface of the brain with intermittent activation.
- Trial name
- EpCS-D (NCT00565617)
- Testing
- Synergy, Epidural cortical stimulation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Medical University of South Carolina
Unipolar Depression, Treatment Resistant Depression
Home-administered tDCS for Treatment of Depression
This study will determine the safety and efficacy of home administered tDCS in adults with unipolar depression. The device used to administer tDCS will be the Soterix Medical 1X1 mini-CT.
- Trial name
- NCT04781127
- Testing
- Soterix Medical mini-CT tDCS stimulator
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Soterix Medical
Major Depressive Disorder
Adjunct Minocyline in Treatment-resistant Depression
This study examines the antidepressant efficacy of minocycline as an adjunct to an antidepressant standard treatment (AD-ST), for patients with unipolar major depressive disorder (MDD).
- Trial name
- Mino-TRD (NCT02456948)
- Testing
- Minocycline
- Where
- 9 sites in Germany
- Volunteers
- 168 people
- Sponsor
- Charite University, Berlin, Germany
Major Depressive Disorder
Efficacy of SEROQUEL in Selective Serotonin Reuptake Inhibitors (SSRI)-Resistant Major Depressive Disorder
An open-label, non-comparative, multi-centre, phase II prospective trial to assess the efficacy of Quetiapine fumarate augmentation of selective serotonin reuptake inhibitors (SSRIs) in SSRI-resistant major depressive disorder.
- Trial name
- UNIQUE (NCT00733668)
- Testing
- Quetiapine fumarate (Seroquel)
- Where
- 4 sites in Belgium
- Sponsor
- AstraZeneca
Major Depression
Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism
Reduction of volume of the hippocampus has been associated with major depression in many studies. It has been suggested that antidepressants may protect against hippocampus volume loss in humans associated with multiple episodes…
- Trial name
- NCT00704860
- Testing
- Open label pharmacotherapy
- Where
- Canada
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- University of Ottawa
Depression, Depressive Disorder
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
The purpose of this study is to compare the relative effectiveness of 20 and 60 minutes of Low-Field Magnetic Stimulation in relieving symptoms in patients with major depression who are treatment resistant.
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Treatment-resistant, Depressive Disorder, Major
- Trial name
- NCT02452892
- Testing
- LFMS
- Where
- 12 sites in United States
- Volunteers
- 122 people
- Sponsor
- Tal Medical, Inc.
Depressive Disorder
Cerebral Neuroinflammation During Major Depressive Episode
the investigators make the following assumptions: 1) neuroinflammation in MDD can be measured by the [18 F ] DPA- 714 ; 2) it is accompanied by anatomical and functional changes in the frontal subcortical loops, strongly involved…
- Trial name
- InflaDep (NCT03314155)
- Testing
- Cerebral neuroinflammation evaluation
- Where
- 4 sites in France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital, Toulouse
Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
Feasibility Trial of Exercise as a Priming Strategy for rTMS Treatment in Difficult-to-Treat Depression
The goal of this study is to collect feasibility data on combining structured exercise aimed to improve physical fitness, and intermittent TBS (iTBS) in treating individuals diagnosed with difficult-to-treat depression who are…
- Trial name
- NCT06773949
- Testing
- Theta burst stimulation
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- The Royal Ottawa Mental Health Centre
Depression
RESIST : Administration of MAP4343 in Antidepressant Non-Responders Patients Experiencing a Major Depressive Episode
The study is a phase II, double-blind, randomized, placebo controlled, parallel, multicentric study in 110 patients with drug resistant depression.
- Trial name
- NCT03870776
- Testing
- MAP4343
- Where
- 10 sites in France
- Volunteers
- 126 people
- Sponsor
- Mapreg
Magnetic Resonance Imaging, Major Depression
Ketamine Alcohol (in Treatment-Resistant Depression)
A single subanesthetic dose infusion of the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has rapid and robust antidepressant effects in patients with treatment-refractory major depressive disorder (TRD).
- Conditions
- Magnetic Resonance Imaging, Major Depression, Alcoholism
- Trial name
- NCT02122562
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Mark Niciu
Depressive Disorder, Treatment-Resistant, Depressive Disorder, Major
Behavioural Activation Therapy and Esketamine for Resistant Depression
This is a randomized clinical trial to test the effectiveness of combining a proven psychological intervention called behavioural activation therapy alongside esketamine treatment for treatment resistant major depressive episodes…
- Conditions
- Depressive Disorder, Treatment-Resistant, Depressive Disorder, Major, Bipolar Disorder
- Trial name
- NCT06431386
- Testing
- Behavioural Activation (BA) Therapy, Esketamine
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- The Royal's Institute of Mental Health Research
Healthy
A Multiple Ascending Dose Study of BCI-838 in Healthy Volunteers
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BCI-838 and its metabolite BCI-632 in healthy male and female subjects.
- Trial name
- NCT01548703
- Testing
- BCI-838
- Where
- Netherlands
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- BrainCells Inc.
Depression, Major Depressive Disorder
Oxytocin and Tibolone Adjuncts in Treatment Resistant Depression - A Pilot Study
The purpose of this study is to determine whether an oxytocin ad-on, or oxytocin and tibolone ad-on can induce a response to antidepressants in patients with treatment resistant depression.
- Trial name
- NCT01239888
- Testing
- Oxytocin, Oxytocin and Tibolone
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- The Alfred
Treatment-resistant Depression
Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) I
Our hypothesis is that targeted propofol infusion in treatment-resistant depressed patients will induce slow wave activity during sedation and augment subsequent sleep slow wave activity.
- Trial name
- NCT04680910
- Testing
- Propofol, Electroencephalography (EEG), Slow-Wave Activity
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Washington University School of Medicine
Depression
Effectiveness of Pramipexole for Treatment-Resistant Depression
This study will evaluate the effectiveness of pramipexole (Mirapex) in managing treatment-resistant depression.
- Trial name
- NCT00231959
- Testing
- Pramipexole (Mirapex)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Massachusetts General Hospital
Treatment Resistant Depression, Major Depressive Disorder
pBFS-guided rTMS Over DMPFC for Treatment-Resistant Depression
This study is a multicenter, randomized, double-blind, placebo-controlled trial aimed at exploring the effectiveness and safety of rTMS intervention with DMPFC targets guided by pBFS in patients with treatment-resistant…
- Trial name
- NCT06350396
- Testing
- active rTMS treatment
- Where
- 5 sites in China
- Volunteers
- 270 people
- Sponsor
- Changping Laboratory
Major Depressive Disorder (MDD), Treatment-resistant Depression (TRD)
Comparison of Efficacy of Minocyclin and Celecoxib as Adjunctive Treatment in Treatment Resistant Cases of Major Depressive Disorder
This randomized controlled study was conducted to compare the effectiveness of minocycline and celecoxib as add-on treatments in patients with treatment-resistant major depressive disorder.
- Trial name
- NCT07804979
- Testing
- Minocycline, Celecoxib
- Where
- Pakistan
- Volunteers
- 78 people
- Sponsor
- Lahore General Hospital
Major Depressive Disorder, MDD
A Non Interventional Study to Investigating the Ratio of Mis-diagnosed Bipolar Symptoms in Patient With Major Depressive Disorder (MDD)
The study will only detect hypomanic symptoms in treatment resistant MDD patients by mean of HCL-32 administration. Further re-evaluation of MDD diagnosis is not a direct aim of the study.
- Trial name
- Improve (NCT01344733)
- Where
- 29 sites in Italy
- Volunteers
- 660 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Treatment Resistant Geriatric Depression in Primary Care
This study involves collaboration between McLean Hospital, Geriatric Medicine at the Cambridge Health Alliance (CHA) and other sites within the Partners and Harvard Medical School network.
- Trial name
- NCT01392287
- Testing
- Memantine
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Major Depressive Disorder (MDD)
Accelerated Neuromodulation of Anterior Cingulate Cortex for Depression
The goal of this clinical trial is to test whether an accelerated deep Transcranial Magnetic Stimulation (dTMS) protocol can reduce depressive symptoms in older adults (ages 60-85) with Major Depressive Disorder (MDD) who have…
- Trial name
- NACC-D (NCT07212465)
- Testing
- Active Brainsway H7-Coil Deep TMS System
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Rotman Research Institute at Baycrest